The present invention describes the use of a 5HT3-antagonist, in combination with a 6-propylamino-4,5,6,7-tetrahydro-1,3-benzothiazole-2-amine, to reduce adverse effects and to facilitate the neuroprotective treatment of a patient suffering from a synucleinopathic disorder to enable a therapeutically effective 6-propylamino-4,5,6,7-tetrahydro-1,3-benzothiazole-2-amine daily dose without the dose-limiting adverse effects caused by pramipexole when administered alone.

The present invention describes the use of a 5HT3-antagonist, in combination with a 6-propylamino-4,5,6,7-tetrahydro-1,3-benzothiazole-2-amine, to reduce adverse effects and to facilitate the neuroprotective treatment of a patient suffering from a synucleinopathic disorder to enable a therapeutically effective 6-propylamino-4,5,6,7-tetrahydro-1,3-benzothiazole-2-amine daily dose without the dose-limiting adverse effects caused by pramipexole when administered alone.

The present invention describes the use of a 5HT3-antagonist, in combination with a 6-propylamino-4,5,6,7-tetrahydro-1,3-benzothiazole-2-amine, to reduce adverse effects and to facilitate the neuroprotective treatment of a patient suffering from a synucleinopathic disorder to enable a therapeutically effective 6-propylamino-4,5,6,7-tetrahydro-1,3-benzothiazole-2-amine daily dose without the dose-limiting adverse effects caused by pramipexole when administered alone.

Using one or more parasympathomimetic drugs alone or together, or in combination with one or more alpha agonists to create optically beneficial miosis to temporarily create multifocality in a pseudophakic patient to treat presbyopia. A pharmaceutical preparation comprising a therapeutically effective amount of one or more parasympathomimetic drugs or cholinesterase inhibitors, alone or in combination with or a pharmaceutically acceptable salt thereof, in combination with one or more alpha agonists or antagonists, or a pharmaceutically acceptable salt thereof. A method for creating multifocality in a pseudophakic patient, reducing symptoms of presbyopia in a patient having an eye or both eyes through administering to an eye or eyes a pharmaceutically effective amount of the ophthalmic preparation is also disclosed.

Disclosed are compounds of following formula (I): ##STR00001##
in which all symbols have the same meanings as the definitions described in the specification; or a salt thereof. The compounds or a salt thereof are useful as a prophylactic and/or therapeutic agent for cancer, Huntington's disease, Alzheimer's disease and the like.

The invention features solid dosage forms of N-1-pyrrolidine-N-5-(3-trifluoromethoxy)phenyl biguanide, or a pharmaceutically acceptable salt thereof, where the solid dosage form includes an enteric coating and uses thereof.

The invention features solid dosage forms of N-1-pyrrolidine-N-5-(3-trifluoromethoxy)phenyl biguanide, or a pharmaceutically acceptable salt thereof, where the solid dosage form includes an enteric coating and uses thereof.

This invention relates to compositions and methods for identifying the network that modulates, controls, or otherwise influences BCL-2 pathway inhibition, for example, energy-stress signaling, mitochondrial metabolism, vesicle transport, ribosomal components, and proteolysis. The invention also relates to identifying and modulating target genes and/or target gene products that modulate, control, or otherwise influence BCL-2 pathway inhibition.

This invention relates to compositions and methods for identifying the network that modulates, controls, or otherwise influences BCL-2 pathway inhibition, for example, energy-stress signaling, mitochondrial metabolism, vesicle transport, ribosomal components, and proteolysis. The invention also relates to identifying and modulating target genes and/or target gene products that modulate, control, or otherwise influence BCL-2 pathway inhibition.

Drug delivery systems and wearable articles including the drug delivery systems are provided. The drug delivery systems may include a substrate coated with at least one polymer and at least one active compound. The substrate is operable to include yarns, yarn precursors, threads, filaments, fibers, and/or other suitable substrates. Methods for manufacturing drug delivery systems are also provided. The methods are operable to include disposing a solution including a monomer and an active compound on the substrate. The methods are also operable to include exposing the solution and the substrate to UV light to initiate polymerization of the solution.